Omid Hamid on Responses to Single Agent Immunotherapies Compared to Combination


Omid Hamid, MD, compares the responses of patients with melanoma on single-agent immunotherapy treatment to those on combination therapy treatments.

Omid Hamid, MD, chief of Translational Research and Immunotherapy at The Angeles Clinic, talks about patient responses with single-agent immunotherapy and combination therapies in melanoma.

Hamid explains that the response rate for single-agent immunotherapy treatment is approximately 40%, and for combination treatments, it is approximately 57%. However, these data do not give much information about the long-term benefits of these therapies. Hopefully, comparisons of the overall survival with combination treatments and with single-agent treatment will be forthcoming.

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
© 2024 MJH Life Sciences

All rights reserved.